argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
May 08, 2026
Read MoreViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
May 05, 2026
Read MoreViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Mar 30, 2026
Read MoreVertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
Mar 09, 2026
Read Moreargenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Feb 26, 2026
Read MoreU.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
Feb 12, 2026
Read More